Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
M.D. Anderson Cancer Center Genentech |
---|---|
Information provided by: | M.D. Anderson Cancer Center |
ClinicalTrials.gov Identifier: | NCT00336648 |
Primary Objective:
1. To assess resectability rate in patients undergoing gemcitabine plus Avastin-based chemoradiation followed by pancreaticoduodenectomy for adenocarcinoma of the pancreas.
Secondary Objectives:
Condition | Intervention | Phase |
---|---|---|
Pancreatic Neoplasms |
Drug: Bevacizumab Drug: Gemcitabine Procedure: Radiation Therapy |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Pilot Study of Preoperative Gemcitabine and Bevacizumab-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreas |
Estimated Enrollment: | 31 |
Study Start Date: | June 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
U.T. M.D. Anderson Cancer Center | |
Houston, Texas, United States, 77030 |
Principal Investigator: | Douglas Evans, MD | M.D. Anderson Cancer Center |
Study ID Numbers: | 2005-0784 |
Study First Received: | June 13, 2006 |
Last Updated: | September 26, 2007 |
ClinicalTrials.gov Identifier: | NCT00336648 |
Health Authority: | United States: Food and Drug Administration |
Pancreatic Neoplasms Bevacizumab Gemcitabine |
Radiation Therapy adenocarcinoma of the pancreatic head adenocarcinoma of the uncinate process |
Digestive System Neoplasms Pancreatic Neoplasms Endocrine System Diseases Bevacizumab Pancrelipase Carcinoma Digestive System Diseases |
Gastrointestinal Neoplasms Pancreatic Diseases Endocrinopathy Adenocarcinoma Gemcitabine Neoplasms, Glandular and Epithelial Endocrine Gland Neoplasms |
Antimetabolites Anti-Infective Agents Neoplasms by Histologic Type Antimetabolites, Antineoplastic Immunologic Factors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Growth Substances Physiological Effects of Drugs Enzyme Inhibitors |
Angiogenesis Inhibitors Antiviral Agents Immunosuppressive Agents Pharmacologic Actions Neoplasms Neoplasms by Site Radiation-Sensitizing Agents Therapeutic Uses Growth Inhibitors Angiogenesis Modulating Agents |